Breast cancer
Therapeutic area
Oncology
Rare disease
No
- Definition
- A primary or metastatic malignant neoplasm involving the breast. The vast majority of cases are carcinomas arising from the breast parenchyma or the nipple. Malignant breast neoplasms occur more frequently in females than in males.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- No
- Listing at source
- Listed
- Condition name
- Breast cancer
- Therapeutic area
- Oncology
- breast cancer
- breast tumor
- breast tumour
- mammary tumor
- mammary tumour
- breast cancer
- cancer of breast
- malignant breast neoplasm
- malignant breast tumor
- malignant breast tumour
- malignant neoplasm of breast
- malignant neoplasm of the breast
- malignant tumor of breast
- malignant tumor of the breast
- malignant tumour of breast
- malignant tumour of the breast
- primary breast cancer
- All therapeutic areas
- Oncology
- Severity
- Severe
- MONDO ID
- MONDO:0007254
- Parent condition
- MONDO:0003274
Related records
Broader conditions (12)
- Breast disorder
- Breast neoplasm
- Cancer
- Cancer or benign tumor
- Disease
- Disease by body system or component
- Disease by etiologic mechanism
- Human disease
- Neoplasm
- Neoplasm of thorax
- Neoplastic disease or syndrome
- Thoracic cancer
Narrower conditions (97)
- Acantholytic variant squamous cell breast carcinoma
- Acinic cell breast carcinoma
- Adenoid cystic breast carcinoma
- Adenosquamous breast carcinoma
- Atypical lobular breast hyperplasia
- Basal-like breast carcinoma
- Bilateral breast carcinoma
- Breast adenocarcinoma
- Breast angiosarcoma
- Breast apocrine carcinoma
- Breast apocrine carcinoma in situ
- Breast carcinoma
- Breast carcinoma by gene expression profile
- Breast carcinoma in situ
- Breast columnar cell mucinous carcinoma
- Breast cystic hypersecretory carcinoma
- Breast diffuse large B-cell lymphoma
- Breast ductal adenocarcinoma
- Breast extraskeletal osteosarcoma
- Breast fibrosarcoma
Trials (10,963)
- 'ADVANCE' (A Pilot Trial)
- 'OLAP' (OLAparib Regulatory Post-marketing Surveillance)
- " Role of Diffusion Weighted Image in the Diagnosis and Follow up of Breast Cancer"
- "Can Do" Versus "Do Do" in Patients With Breast Cancer
- "Curcumin" in Combination With Chemotherapy in Advanced Breast Cancer
- "Effectiveness of Community Health Workers in Breast Cancer Prevention in Jumla: a Cluster Randomized Trials
- "Electro Acupuncture in the Treatment and Management of Chemotherapy Induced Peripheral Neuropathy"
- "Observational, Retrospective and Prospective, Non-interventional, Multicentre on the Use of Genomic Testing in the Management of Early Stage HR+/HER2- Breast Cancer"
- "Prevention of Paclitaxel-Induced Peripheral Neuropathy in Breast Cancer Patients"
- "Serratus Anterior Plane Block" Versus "Serratus Posterior Superior Plane Intercostal Plane Block" for Patients Undergoing Breast Surgery
- "Studying The Role of Key Epigenetic Mediators in Breast Cancer Patients"
- "The Efficacy of 'Radioguided Occult Lesion Localization' (ROLL) Versus 'Wire-guided Localization' (WGL) in Breast Conserving Surgery for Non-palpable Breast Cancer: a Randomized Clinical Trial"
- (Oncotype DX®) in Estrogen Receptor Positive (ER+) HER-2 Negative (HER 2-) 1-3 Node Positive (pN1) Breast Cancer
- [177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer
- [18F] F-GLN by PET/CT in Breast Cancer
- [18F]FES PET/CT for the Detection of Distant Metastasis in Low-grade ER-positive Stage III Breast Cancer
- [18F]FES PET/CT in Endocrine Refractory Breast Cancer
- [18F]FLT PET/CT in Rb+ Metastatic Breast Cancer
- [18F]ISO-1 Positron Emission Tomography (PET/CT) in Primary Breast Cancer
- [68]GA-FAPI-46 PET/CT for the Diagnosis of Metastatic Lesions in Patients With Lobular Breast Cancer (ICL).
Approved drugs (49)
- Abemaciclib
- Alpelisib
- Anastrozole
- Atezolizumab
- Bevacizumab
- Capecitabine
- Capivasertib
- Cyclophosphamide
- Denosumab
- Dexrazoxane hydrochloride
- Docetaxel
- Doxorubicin hydrochloride
- Epirubicin hydrochloride
- Eribulin mesylate
- Estradiol
- Estrogens, conjugated
- Estrogens, esterified
- Everolimus
- Exemestane
- Fluoroestradiol F-18
Drugs in development (782)
- .ALPHA.-tocopheryloxyacetic acid Phase 1
- (+)-secoisolariciresinol Phase 2
- 2X-121 Phase 2
- 7-ethyl-10-hydroxycamptothecin Phase 2
- Abexinostat Phase 2
- Abiraterone acetate Phase 3
- ABT 737 Phase 1
- ABT-751 Phase 2
- Acetaminophen Phase 2
- Acetylcysteine Phase 1
- Acolbifene Phase 3
- Acolbifene hydrochloride Phase 2
- Adagloxad simolenin Phase 3
- Adavosertib Phase 2
- Adebrelimab Phase 2
- Aderbasib Phase 1
- ADG-106 Phase 1
- Afatinib Phase 3
- Afatinib dimaleate Phase 3
- Afeletecan Phase 1
Other linked drugs (46)
- Anatumomab mafenatox
- Arcitumomab
- Cefazolin sodium
- Chlorophenothane
- CMB-401
- Crocin
- Datelliptium chloride
- Dexrazoxane
- Dextrose
- Diclofenac
- Disitamab
- Duloxetine
- Fadrozole
- Fenofibrate
- Formestane
- FOXY-5
- Gadobutrol
- Gestrinone
- Indium in 111 satumomab pendetide
- Levobupivacaine